To date, no randomized trials and fewer than 300 cases of urachal carcinomas have been reported in the literature. As a result, limited information exists regarding the effective management of these cancers, especially knowledge concerning the most effective chemotherapeutic agents against atypical bladder cancers with his- tological and biological features similar to those of bowel cancers. Most urachal carcinomas are mucin-producing enteric type adeno- carcinomas that occasionally may exhibit signet ring cells morphology.1 The prognosis of patients with recurrent urachal car- cinoma is extremely poor. We report a case of metastatic urachal carcinoma in which the immunohistochemical profile’s similarities to that of colon cancer led to treatment with FOLFIRI plus bevacizumab, which is a specific first-line chemotherapy of colon cancer.